Floatz logo

Irinotecan

Mucinous Adenocarcinoma

Stony Brook UniversitySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Mucinous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3B
Docetaxel
National Cancer Institute (NCI)
Phase 3B
Eloxatin
University Hospital, Akershus
Phase 2CCC
Nivolumab
University Hospital, Akershus
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Samuraciclib
University Health Network, Toronto
Phase 1/2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →